Clinical Trials Logo

Relapsed Hematologic Malignancy clinical trials

View clinical trials related to Relapsed Hematologic Malignancy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03096821 Completed - Clinical trials for Relapsed Hematologic Malignancy

Extended Analysis for Leukemia/Lymphoma Treatment

EXALT
Start date: September 2015
Phase:
Study type: Observational

Patients with relapsed/ refractory acute leukemia and relapsed/ refractory aggressive lymphoma harboring an activating genetic alteration (gene mutation, gene fusion) or drug-able biomarker / activated signal transduction pathway and resistant to any approved treatment modality will be eligible for this study. The investigators aim to combine DNA sequencing-based molecular profiling with an ex vivo high-throughput drug screening strategy. For the latter method, viable cells are obtained from the individual patient's lymphoma or leukemia in order to determine i)the expression of relevant therapeutic target molecules and ii)the ex vivo response of the patient's cancer cells to a panel of agents with anticancer activity. In addition, analysis of tumor stroma cells will provide information about the differential target expression and cellular sensitivity aiming at the evaluation of a therapeutic safety window. Thereby, biological material will have to be accessed within 4 weeks before onset of individualized treatment (real-time biopsy). Bioinformatic data-management based on a Bayesian statistical approach will support individualized treatment decisions in this controlled clinical approach.